Data / Form D filings / Koligo Therapeutics Ltd
Koligo Therapeutics Ltd: Form D filing
Koligo Therapeutics Ltd, a biotechnology company in Sydney, Australia, filed a Form D with the SEC in 2019. The latest, on March 20, 2019, reports $38,000 sold of a $400,000 offering to 2 investors.
Find out what Koligo Therapeutics Ltd does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- LEVEL 5, 126 PHILLIP STREET, Sydney, Australia, 2000
- Phone
- 01161292999690
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Australia
- Year incorporated
- 2018
- Revenue range
- $1,000,001 - $5,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1771249
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 20, 2019 | New notice | $400,000 | $38,000 | $362,000 | 2 | Mar 12, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Lehman | Executive Officer, Director | |
| Ariel Sivikofsky | Executive Officer | |
| Peter James | Director | |
| Jethro Marks | Director | |
| Robert Clisdell | Director | |
| Stuart Williams | Executive Officer, Director |
Every Form D from the week of Mar 18, 2019 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Koligo Therapeutics Ltd reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.